Renin–angiotensin system blockade alone or combined with ETA receptor blockade: effects on the course of chronic kidney disease in 5/6 nephrectomized Ren-2 transgenic hypertensive rats
- 17 February 2017
- journal article
- research article
- Published by Taylor & Francis in Clinical and Experimental Hypertension
- Vol. 39 (2) , 183-195
Abstract
Background: Early addition of endothelin (ET) type A (ETA) receptor blockade to complex renin–angiotensin system (RAS) blockade has previously been shown to provide better renoprotection against progression of chronic kidney disease (CKD) in Ren-2 transgenic hypertensive rats (TGR) after 5/6 renal ablation (5/6 NX). In this study, we examined if additional protection is provided when ETA blockade is applied in rats with already developed CKD. Methods: For complex RAS inhibition, an angiotensin-converting enzyme inhibitor along with angiotensin II type 1 receptor blocker was used. Alternatively, ETA receptor blocker was added to the RAS blockade. The treatments were initiated 6 weeks after 5/6 NX and the follow-up period was 50 weeks. Results: When applied in established CKD, addition of ETA receptor blockade to the complex RAS blockade brought no further improvement of the survival rate (30% in both groups); surprisingly, aggravated albuminuria (588 ± 47 vs. 245 ± 38 mg/24 h, p < 0.05) did not reduce renal glomerular injury index (1.25 ± 0.29 vs. 1.44 ± 0.26), did not prevent the decrease in creatinine clearance (203 ± 21 vs. 253 ± 17 µl/min/100 g body weight), and did not attenuate cardiac hypertrophy to a greater extent than observed in 5/6 NX TGR treated with complex RAS blockade alone. Conclusions: When applied in the advanced phase of CKD, addition of ETA receptor blockade to the complex RAS blockade brings no further beneficial renoprotective effects on the CKD progression in 5/6 NX TGR, in addition to those seen with RAS blockade alone.Keywords
Funding Information
- Czech Health Research Council (15-28671A)
This publication has 41 references indexed in Scilit:
- The next generation of therapeutics for chronic kidney diseaseNature Reviews Drug Discovery, 2016
- Regression of Renal Disease by Angiotensin II Antagonism Is Caused by Regeneration of Kidney VasculatureJournal of the American Society of Nephrology, 2016
- Renal Autoregulation in Health and DiseasePhysiological Reviews, 2015
- Chronic kidney disease: global dimension and perspectivesThe Lancet, 2013
- Treatment of chronic kidney diseaseKidney International, 2012
- Similar renoprotection after renin‐angiotensin‐dependent and ‐independent antihypertensive therapy in 5/6‐nephrectomized Ren‐2 transgenic rats: are there blood pressure‐independent effects?Clinical and Experimental Pharmacology and Physiology, 2010
- Complementary effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in slowing the progression of chronic kidney diseaseAmerican Heart Journal, 2009
- Review: Renal protection by inhibition of the renin-angiotensin-aldosterone systemJournal of the Renin-Angiotensin-Aldosterone System, 2009
- Progression of chronic kidney disease: insights from animal modelsCurrent Opinion in Nephrology and Hypertension, 2006
- A novel potent vasoconstrictor peptide produced by vascular endothelial cellsNature, 1988